Examining the cardiorenal benefits of SGLT2 inhibitors for people with type 2 diabetes

CAN-eng

$0

free

Mainpro+

30 mins

Endocrinology

0.25 Credits

This course is expired! Browse All Courses
LEARN MORE

Course Description

In recent landmark trials, certain SGLT2 inhibitors have demonstrated cardiovascular and renal benefits in patients with type 2 diabetes.

This video helps clinicians navigate the most recent clinical evidence for SGLT2 inhibitors and reviews the updated recommendations from the Diabetes Canada guidelines. The goal is to help clinicians apply the cardiorenal evidence to primary care practice and increase their confidence in identifying patients who would benefit from SGLT2i and initiating SGLT2i in those patients.

This program has received an educational grant or in-kind support from Astra Zeneca.

Course Details

Expiry Date: 2022-09-27

Professions: Physician

Faculty

Louis Girard, MD, MBT, FRCPC

Peter J. Lin, MD, CCFP

Christine Palmay, Hons BArt+Sci, MD, CCFP

Phuongbich Nguyen, MD

Accreditation

This self-learning program has been certified by the College of Family Physicians of Canada for up to 0.25 Mainpro+ credits.

Cert+ Program ID#: 194412

Learning Objective(s)

After viewing this expert brief video, participants will be better able to:

  • Describe the cardiovascular and renal risks associated with type 2 diabetes
  • Discuss the cardiovascular and renal outcome results of SGLT2 inhibitors in clinical trials and their relevance to primary care practice
  • Recommend SGLT2 inhibitors that have demonstrated cardiorenal protection in clinical trials and are in line with the recommendations from Diabetes Canada guidelines
This course is expired! Browse All Courses